Evidence map›Paper›PMID 41279536›Full record

ArticlebioRxiv : the preprint server for biology2025

In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell Disease.

Ying Qian, Nazanin Ahmadi Daryakenari, Melissa Hallow, Lu Lu, Pierre A Buffet, Ming Dao, He Li, George Em Karniadakis

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ying QianSchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, GA 30602.
Nazanin Ahmadi DaryakenariCenter for Biomedical Engineering, School of Engineering, Brown University, Providence, RI 02912.
Melissa HallowSchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, GA 30602.
Lu LuDepartment of Statistics and Data Science, Yale University, New Haven, CT 06511.
Pierre A BuffetUniversité Paris Cité and Université des Antilles, Inserm, Biologie Intégrée du Globule Rouge, 75015, Paris, France.
Ming DaoDepartment of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
He LiSchool of Chemical, Materials, and Biomedical Engineering, University of Georgia, Athens, GA 30602.
George Em KarniadakisDivision of Applied Mathematics, Brown University, Providence, RI 02912.

Funding

Multifidelity and multiscale modeling of the spleen function in sickle cell disease with in vitro, ex vivo and in vivo validationsR01HL154150 · NHLBI · BROWN UNIVERSITY · PI Pierre BUFFET, Ming Dao · 2020 to 2026
$3.9M
A deep learning-enhanced multiphysics and multiscale framework for predictive modeling of inflammation-induced thrombosisR21HL168507 · NHLBI · UNIVERSITY OF GEORGIA · PI FRYDMAN, GALIT H., LI, HE · 2024 to 2025
$393k
NHLBI NIH HHS R01 HL154150NHLBI NIH HHS R21 HL168507
6 · The paper itself

Abstract

Sickle cell disease (SCD) is a genetic disorder that affects approximately 100,000 individuals in the United States and millions globally. Although curative therapies, such as stem cell transplant and gene therapy, are available, their application is limited by high cost and donor availability. Consequently, drug therapy remains the most feasible treatment option for the majority of patients with SCD. To date, only four drugs have been approved by the FDA, but none of these treatments comprehensively address all SCD-related symptoms or crises, suggesting the pressing need for developing new drugs. Several high-throughput screening campaigns have been performed for SCD drug discovery based on the

Identifiers

PMID41279536
PMCPMC12633374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.